| ECM-receptor interaction |
2.36 |
0.00e+0 |
80/88 (90.91%) |
SPP1;THBS1;THBS2;...
|
| Dilated cardiomyopathy |
2.21 |
0.00e+0 |
86/96 (89.58%) |
ITGA4;TNNC1;DES;...
|
| Hypertrophic cardiomyopathy |
2.09 |
0.00e+0 |
81/90 (90%) |
ITGA4;TNNC1;DES;...
|
| Focal adhesion |
1.98 |
2.59e-3 |
180/201 (89.55%) |
SPP1;THBS1;THBS2;...
|
| Sulfur metabolism |
1.97 |
2.08e-3 |
9/10 (90%) |
PAPSS2;MPST;TST;...
|
| Arrhythmogenic right ventricular cardiomyopathy |
1.90 |
3.46e-3 |
70/77 (90.91%) |
ITGA4;DES;LAMA2;...
|
| ABC transporters |
1.83 |
1.04e-2 |
37/45 (82.22%) |
ABCA3;ABCC4;ABCC3;...
|
| Protein digestion and absorption |
1.82 |
1.56e-2 |
78/103 (75.73%) |
SLC3A1;COL10A1;COL14A1;...
|
| Adipocytokine signaling pathway |
1.76 |
2.88e-2 |
64/69 (92.75%) |
PRKCQ;CD36;IRS1;...
|
| Adrenergic signaling in cardiomyocytes |
1.75 |
3.22e-2 |
130/150 (86.67%) |
ADRB2;TNNC1;PLN;...
|
| Insulin resistance |
1.73 |
3.59e-2 |
96/108 (88.89%) |
PRKCQ;CD36;PRKCB;...
|
| Cardiac muscle contraction |
1.71 |
4.07e-2 |
64/87 (73.56%) |
TNNC1;MYL2;TPM3;...
|
| Regulation of lipolysis in adipocytes |
1.69 |
4.31e-2 |
52/55 (94.55%) |
ADRB2;FABP4;PLAAT3;...
|
| Lipid and atherosclerosis |
-1.56 |
4.87e-2 |
190/215 (88.37%) |
VCAM1;PPP3CC;PLCB2;...
|
| Drug metabolism |
-1.57 |
4.74e-2 |
78/151 (51.66%) |
ADH6;FMO1;GSTT2;...
|
| Ferroptosis |
-1.58 |
4.50e-2 |
36/41 (87.8%) |
SLC39A8;GCLM;STEAP3;...
|
| Staphylococcus aureus infection |
-1.58 |
4.42e-2 |
72/95 (75.79%) |
FCGR3B;HLA-DRB1;HLA-DPA1;...
|
| Pathways of neurodegeneration |
-1.59 |
4.30e-2 |
354/475 (74.53%) |
BAK1;COX7A2L;DCTN5;...
|
| Mineral absorption |
-1.60 |
4.13e-2 |
48/60 (80%) |
FTL;MT2A;ATOX1;...
|
| Asthma |
-1.63 |
3.22e-2 |
25/31 (80.65%) |
FCER1A;HLA-DRB1;HLA-DPA1;...
|
| Systemic lupus erythematosus |
-1.68 |
1.99e-2 |
45/135 (33.33%) |
CD80;C8B;ELANE;...
|
| Graft-versus-host disease |
-1.68 |
2.04e-2 |
32/42 (76.19%) |
IL1B;CD80;PRF1;...
|
| Spinocerebellar ataxia |
-1.69 |
2.09e-2 |
128/143 (89.51%) |
PSMA6;AKT3;ATG101;...
|
| Oxidative phosphorylation |
-1.70 |
2.15e-2 |
93/133 (69.92%) |
COX17;ATP5F1C;NDUFA6;...
|
| Protein export |
-1.70 |
2.26e-2 |
17/23 (73.91%) |
SPCS3;SRP14;SPCS1;...
|
| IL-17 signaling pathway |
-1.73 |
1.80e-2 |
84/94 (89.36%) |
TRAF6;CCL17;CHUK;...
|
| RNA transport |
-1.78 |
1.29e-2 |
128/186 (68.82%) |
EIF3E;EIF1;EIF5;...
|
| DNA replication |
-1.85 |
5.37e-3 |
34/36 (94.44%) |
FEN1;PRIM1;RNASEH2B;...
|
| Mismatch repair |
-1.86 |
5.73e-3 |
22/23 (95.65%) |
SSBP1;RFC2;RFC4;...
|
| Antigen processing and presentation |
-1.87 |
2.73e-3 |
60/78 (76.92%) |
HSP90AB1;KLRC3;HLA-DRB1;...
|
| Protein processing in endoplasmic reticulum |
-1.88 |
2.94e-3 |
127/171 (74.27%) |
SSR3;SKP1;CKAP4;...
|
| Autoimmune thyroid disease |
-1.91 |
3.18e-3 |
46/53 (86.79%) |
FASLG;IFNA1;IL5;...
|
| Ribosome biogenesis in eukaryotes |
-1.93 |
8.68e-4 |
52/108 (48.15%) |
GNL2;POP1;REXO5;...
|
| Nucleotide excision repair |
-1.94 |
9.55e-4 |
40/47 (85.11%) |
CCNH;ERCC4;XPA;...
|
| Allograft rejection |
-1.98 |
0.00e+0 |
32/38 (84.21%) |
FASLG;IL5;IL4;...
|
| Type I diabetes mellitus |
-1.99 |
0.00e+0 |
38/43 (88.37%) |
IL1B;CD80;PRF1;...
|
| Amyotrophic lateral sclerosis |
-2.06 |
0.00e+0 |
267/364 (73.35%) |
PSMC4;PPP3CC;DNAI2;...
|
| Huntington disease |
-2.12 |
0.00e+0 |
233/306 (76.14%) |
TBPL1;KIF5A;DNAI1;...
|
| Prion disease |
-2.14 |
0.00e+0 |
209/273 (76.56%) |
PSMC4;PPP3CC;COX5B;...
|
| Parkinson disease |
-2.30 |
0.00e+0 |
176/249 (70.68%) |
ATP5F1C;PSMC5;NDUFA6;...
|
| Proteasome |
-2.49 |
0.00e+0 |
44/46 (95.65%) |
PSMB4;PSME4;PSMC4;...
|
| Spliceosome |
-2.50 |
0.00e+0 |
101/150 (67.33%) |
SRSF1;SYF2;CDC40;...
|
| Ribosome |
-2.73 |
0.00e+0 |
113/158 (71.52%) |
RPS3;RPS2;RPLP0;...
|
